Hot on the trail of companion diagnostics partnerships, Qiagen is teaming up with pharma bigwig Novartis to develop tests for the company's drug portfolio.
A year ago, Myriad Genetics launched its MyRisk Hereditary Cancer multi-gene molecular diagnostic test with great fanfare. Now, the Utah-based company is touting some eye-popping clinical trial results in a bid to reinforce its utility in the marketplace.
POPULAR COMMENT THREADS
With its sights set on growth, German diagnostics outfit Curetis AG has closed a $18.1 million Series B financing round with new investor Qiagen chipping in.
Hologic's effort to cut costs by slimming down its staff came at a price this year. The Bedford, MA-based diagnostics giant was hit with $51.7 million in restructuring charges in 2014, according to a regulatory filing.
LabCorp and CareDx have officially pulled the plug on a previously announced agreement to develop a lupus flare predictor test after completing the first phase of their collaboration.
Amid growing demand for portable, low-cost diagnostics, Indian startup Swasthya Slate is developing a device that could help reduce costs and improve outcomes for patients in developing countries.
As the diagnostics industry explores innovative ways to monitor and contain bacterial infections, Illumina is joining forces with French diagnostic outfit bioMérieux to develop a next-generation sequencing system that can identify infectious bacteria in service labs and hospitals.
From Our Sister Sites
The FDA has slapped down Bristol-Myers Squibb's closely watched hep C drug daclatasvir, handing out a complete response letter for the linchpin drug in its cocktail strategy.
Industry applauded Japan's initiative to create a medical device regulatory regime distinct from that for pharmaceuticals.